Trial halted: testing combo to hold back aggressive lung cancer
NCT ID NCT04373369
Summary
This study tested whether adding a drug called vorolanib to an immunotherapy drug (atezolizumab) could help keep extensive-stage small cell lung cancer from getting worse for a longer time after patients finished standard chemotherapy. It was a Phase 2 trial that enrolled 11 adults who had completed initial chemo-immunotherapy without their cancer progressing. The trial was terminated early, so its full results are unknown.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.